José Baselga

Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

Cancer therapy shapes the fitness landscape of clonal hematopoiesis

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer

ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.

FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer

Pan-Cancer Efficacy of Vemurafenib in <i>BRAF</i> V600-Mutant Non-Melanoma Cancers

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

A view on drug resistance in cancer

Tumour lineage shapes BRCA-mediated phenotypes

Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer

PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression

MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer

Genome doubling shapes the evolution and prognosis of advanced cancers

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

Ado-Trastuzumab Emtansine for Patients With <i>HER2</i>-Mutant Lung Cancers: Results From a Phase II Basket Trial

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

BRAF Inhibition in <i>BRAF</i> ^V600 -Mutant Gliomas: Results From the VE-BASKET Study

Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors

Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) <i>v</i> FULV in patients (pts) with estrogen receptor (ER)-positive, <i>PIK3CA</i> -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.

Abstract 3596: Biomarkers of response to CDK4/6 inhibitor (CDK4/6i) in hormone receptor (HR) positive and HER2-positive breast cancer (BC) patient-derived xenografts (PDX)

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes